发明授权
- 专利标题: Flavivirus vaccine
-
申请号: US16772131申请日: 2018-12-12
-
公开(公告)号: US11931406B2公开(公告)日: 2024-03-19
- 发明人: Patrick Baumhof , Wolfgang Grosse , Edith Jasny , Thomas Kramps , Daniel Voss , Julia Dannenmaier , Valérie Lecouturier , Yves Girerd-Chambaz
- 申请人: CureVac SE , Sanofi Pasteur
- 申请人地址: DE Tübingen
- 专利权人: CureVac SE,Sanofi Pasteur
- 当前专利权人: CureVac SE,Sanofi Pasteur
- 当前专利权人地址: DE Tübingen; FR Lyons
- 代理机构: Parker Highlander PLLC
- 优先权: EP 207141 2017.12.13
- 国际申请: PCT/EP2018/084607 2018.12.12
- 国际公布: WO2019/115635A 2019.06.20
- 进入国家日期: 2020-06-11
- 主分类号: A61K39/12
- IPC分类号: A61K39/12 ; A61P31/14 ; A61K39/00
摘要:
The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.
公开/授权文献
- US20210069315A1 FLAVIVIRUS VACCINE 公开/授权日:2021-03-11
信息查询